Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.44 |
| ▸ | MET | P08581 | 7/20 | 0.44 |
| ▸ | CSF1R | P07333 | 4/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.44 |
| ▸ | FLT3 | P36888 | 4/20 | 0.44 |
| ▸ | BRAF | P15056 | 7/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13861124 | 0.87 | HRH3 (0.43) | KDRMETBRAFHRH3 | |
| SCHEMBL4334234 | 0.86 | MAPK14 (0.47) | KDRMETCSF1RPDGFRBPDGFRA | |
| SCHEMBL14366275 | 0.85 | MET (0.62) | METCSF1RPDGFRBPDGFRAFLT3 | |
| SCHEMBL14366279 | 0.83 | KDR (0.52) | KDRMETCSF1RPDGFRBPDGFRA | |
| SCHEMBL4330283 | 0.81 | MET (0.45) | KDRMETBRAFHRH3 | |
| SCHEMBL4321936 | 0.81 | MET (0.45) | KDRMETPDGFRAMAPK14 | |
| SCHEMBL14366285 | 0.80 | KDR (0.45) | KDRMETCSF1RPDGFRBPDGFRA | |
| SCHEMBL4326890 | 0.80 | MET (0.53) | KDRMETCSF1RPDGFRBPDGFRA | |
| SCHEMBL4331875 | 0.80 | MAPK14 (0.42) | KDRMETCSF1RPDGFRBPDGFRA | |
| SCHEMBL13861081 | 0.80 | HRH3 (0.50) | KDRMETPDGFRBFLT3BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | KDR 7/4885MET 2/4885CSF1R 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.